지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Objectives: To observe the mitigating effects of a Traditional Korean Medicine(TKM) treatment program especially including pharmacopuncture, with Cyclophosphamide and doxorubicin chemotherapy on a both sides breast cancer patient. Methods: AA 74 year-old female patient diagnosed with both sides breast cancer (Right) pT1bpN0M0, (Left) pT1cpN1Mx was admitted to hospital of Dong-eui university in May of 2017. She received Cyclophosphamide and Doxorubicin from May $31^{st}$ to August $2^{nd}$, 2017 followed by TKM treatment consisting of herbal medicine, acupuncture, moxibustion and pharmacopuncture (Trionycis Carapax, Non-toxic Bee Venom, and Cultivated Wild Ginseng Extract) for a period of almost 4 months, from May $13^{th}$ to August $19^{th}$, 2017. Symptoms were evaluated by the grade of chief complaints refer to Common Terminology Criteria for Adverse Events (CTCAE) and Eastern Cooperative Oncology Group (ECOG). Results: TKM including pharmacopuncture alleviated chemotherapy-induced nausea, fatigue, joint pain, diarrhea, insomnia. Conclusions: This case study potentiates TKM with pharmacopuncture's significant efficacy in aiding breast cancer patients suffering from Cyclophosphamide plus Doxorubicin induced adverse effects. Further research should take place for clear understanding of the exact amount of dosage and safety. Moreover it must be accompanied by long-term follow up researches.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Korea Central Cancer Registry / 2017 / Annual report of cancer statistics in Korea in 2015
Early Breast Cancer Trialists’ Collaborative Group / 2000 / Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: and overview of the randomized trials / Lancet 355:1757~1770
Fisher B / 1990 / Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 / J Clin Oncol 8:1483~1496
Levine MN / 1998 / Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node -positive breast cancer. National Cancer Institute of Canada Clinical Trials Group / J Clin Oncol 16:2651~2658
Kim HS / 2010 / Toxicity and tolerability of the TAC regimen for adjuvant chemotherapy among Korean breast cancer patients
Early Breast Cancer Trialists’ Collaborative Group / 2000 / Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: and overview of the randomized trials / Lancet 355:1757~1770
Fisher B / 1990 / Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 / J Clin Oncol 8:1483~1496
Levine MN / 1998 / Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node -positive breast cancer. National Cancer Institute of Canada Clinical Trials Group / J Clin Oncol 16:2651~2658
Kim HS / 2010 / Toxicity and tolerability of the TAC regimen for adjuvant chemotherapy among Korean breast cancer patients
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Loss of endogenous estrogen increases cardiac toxicity by doxorubicin
Journal of Biomedical and Translational Research
2017 .12
-
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
유방암에 대한 한양방 병용 치료 증례 보고 1례
대한한방내과학회지
2017 .01
-
History of Research on Pharmacopuncture in Korea
Journal of Pharmacopuncture
2016 .01
-
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
Cancer Research and Treatment
2019 .01
-
교통사고 후 발생한 경항통에 대한 황련해독탕약침, 봉독약침, 중성어혈약침 치료의 효과 비교 연구: 후향적 관찰 연구
한방재활의학과학회지
2018 .01
-
진행성 유방암에 대한 한양방 병용 치료 치험 1례
대한한방내과학회지
2018 .01
-
유방암에 대한 국내 한의학 연구 동향 고찰- 국내 한의학 논문을 중심으로 -
대한한방내과학회지
2018 .01
-
약침 관련 국내 연구 동향분석
대한예방한의학회지
2018 .01
-
Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
암 환자에 대한 봉독 약침요법의 임상문헌 고찰 및 연구동향 분석
대한한의학회지
2020 .09
-
Quality Control of Pharmacopuncture: A Comparative Study of Good Manufacturing Practice and External Herbal Dispensary Standards
Journal of Pharmacopuncture
2021 .01
-
약침 주입 용량 및 자입 방법에 따른 자극량 차이 연구
대한침구의학회지
2015 .01
-
The Retrospective Study of Advanced Cancer Patients Receiving Integrative Cancer Treatments in single Comprehensive and Integrative Medicine Hospital
대한한의학회지
2022 .09
-
A Retrospective Study on the Clinical Safety of Bee Venom Pharmacopuncture at Craniofacial Acupuncture Points for the Treatment of Facial Disorders
대한침구의학회지
2019 .01
-
Anti-inflammatory activity of doxorubicin on lipopolysaccharide-induced hyperactivation of spleen cells
예방수의학회지
2018 .06
-
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
Cancer Research and Treatment
2016 .01
-
Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
구강건조증 환자에 대한 척추 약침 및 한약 치료 1례
대한한방내과학회지
2019 .01
-
Predictive Factors of Pathologic N2/N3 Disease in Clinical or Pathologic N1 ER+/HER2- Breast Cancer
대한외과학회 학술대회 초록집
2023 .05
이 논문의 저자 정보
최근 본 자료
댓글(0)
0